Table 2. LP-BCSD and non-LP-BCSD in univariate and multivariate analysis.
| Risk Factors | LP-BCSD* | LP-non-BCSD* | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Univariate analyses | Multivariate analyses | Univariate analyses | Multivariate analyses | ||||||
| SHR (95% CI) | p-value | SHR (95% CI) | p-value | SHR (95% CI) | p-value | SHR (95% CI) | p-value | ||
| Age (yr) | |||||||||
| 20–40 | 1 | 1 | 1 | ||||||
| 41–60 | 0.6 (0.57–0.63) | <0.001 | 0.73 (0.69–0.77) | <0.001 | 2.38 (2.04–2.77) | <0.001 | 2.39 (2.05–2.79) | <0.001 | |
| 61–70 | 0.61 (0.57–0.65) | <0.001 | 0.84 (0.78–0.89) | <0.001 | 11.57 (9.95–13.46) | <0.001 | 11.34 (9.74–13.2) | <0.001 | |
| 71–80 | 0.66 (0.62–0.7) | <0.001 | 0.93 (0.87–1.00) | 0.067 | 36.94 (31.79–42.92) | <0.001 | 33.9 (29.14–39.43) | <0.001 | |
| Race | |||||||||
| White | 1 | 1 | 1 | 1 | |||||
| Black | 1.43 (1.35–1.52) | <0.001 | 1.08 (1.02–1.14) | 0.005 | 1.00 (0.95–1.06) | 0.918 | 1.25 (1.18–1.33) | <0.001 | |
| Others | 0.96 (0.90–1.02) | 0.162 | 1.13 (1.08–1.18) | <0.001 | 0.55 (0.51–0.59) | <0.001 | 0.68 (0.64–0.73) | <0.001 | |
| Marital status | |||||||||
| Married | 1 | 1 | 1 | 1 | |||||
| Single | 1.20 (1.14–1.26) | <0.001 | 1.24 (1.16–1.31) | <0.001 | 1.00 (0.95–1.06) | 0.962 | 1.25 (1.18–1.32) | <0.001 | |
| Divorce | 1.16 (1.11–1.20) | <0.001 | 0.92 (0.86–0.98) | 0.007 | 2.45 (2.37–2.53) | <0.001 | 1.38 (1.33–1.42) | <0.001 | |
| Location | |||||||||
| Central portion | 1 | 1 | 1 | 1 | |||||
| Upper-inner quadrant | 0.80 (0.74–0.87) | <0.001 | 1.11 (1.03–1.21) | 0.009 | 0.80 (0.74–0.86) | <0.001 | 0.93 (0.86–1.00) | 0.038 | |
| Lower-inner quadrant | 0.87 (0.80–0.96) | 0.004 | 1.18 (1.07–1.29) | 0.001 | 0.95 (0.87–1.03) | 0.177 | 1.01 (0.93–1.09) | 0.854 | |
| Upper-outer quadrant | 0.75 (0.70–0.80) | <0.001 | 0.85 (0.79–0.91) | <0.001 | 0.85 (0.80–0.90) | <0.001 | 0.99 (0.93–1.05) | 0.686 | |
| Lower-outer quadrant | 0.89 (0.81–0.97) | 0.007 | 1.02 (0.94–1.11) | 0.636 | 0.80 (0.74–0.87) | <0.001 | 0.93 (0.86–1.01) | 0.094 | |
| Overlapping lesion | 0.85 (0.79–0.91) | <0.001 | 0.97 (0.91–1.05) | 0.497 | 0.86 (0.80–0.92) | <0.001 | 0.97 (0.91–1.04) | 0.412 | |
| Histology | |||||||||
| IDC | 1 | 1 | |||||||
| ILC | 1.32 (1.23–1.41) | <0.001 | 1.16 (1.08–1.24) | <0.001 | 1.20 (1.13–1.27) | <0.001 | 0.91 (0.86–0.97) | 0.004 | |
| IDC+ILC | 1.12 (1.05–1.19) | <0.001 | 1.00 (0.94–1.06) | 0.952 | 0.95 (0.90–1.01) | 0.093 | 0.91 (0.85–0.96) | 0.001 | |
| Differentiated grade | |||||||||
| Well | 1 | 1 | 1 | ||||||
| Moderate | 2.49 (2.33–2.65) | <0.001 | 1.95 (1.83–2.09) | <0.001 | 0.91 (0.88–0.95) | <0.001 | 1 (0.96–1.04) | 0.931 | |
| Poor | 3.20 (2.99–3.42) | <0.001 | 2.26 (2.1–2.42) | <0.001 | 0.70 (0.67–0.73) | <0.001 | 0.98 (0.93–1.02) | 0.308 | |
| T-classification† | |||||||||
| T1 | 1 | 1 | 1 | 1 | |||||
| T2 | 2.60 (2.51–2.70) | <0.001 | 1.74 (1.67–1.81) | <0.001 | 0.89 (0.86–0.93) | <0.001 | 1.09 (1.05–1.13) | <0.001 | |
| T3 | 3.72 (3.47–3.98) | <0.001 | 1.86 (1.72–2.00) | <0.001 | 0.74 (0.67–0.82) | <0.001 | 1.12 (1.01–1.24) | 0.036 | |
| T4 | 5.60 (5.06–6.19) | <0.001 | 2.57 (2.31–2.87) | <0.001 | 1.21 (1.05–1.39) | 0.008 | 1.22 (1.05–1.42) | 0.008 | |
| N-classification† | |||||||||
| N0 | 1 | 1 | 1 | 1 | |||||
| N1 | 2.40 (2.30–2.50) | <0.001 | 1.98 (1.90–2.07) | <0.001 | 0.74 (0.71–0.77) | <0.001 | 0.93 (0.89–0.96) | <0.001 | |
| N2 | 4.86 (4.62–5.11) | <0.001 | 3.54 (3.36–3.74) | <0.001 | 0.72 (0.67–0.77) | <0.001 | 0.96 (0.89–1.04) | 0.299 | |
| N3 | 7.73 (7.26–8.22) | <0.001 | 5.25 (4.91–5.62) | <0.001 | 0.64 (0.57–0.72) | <0.001 | 0.86 (0.76–0.97) | 0.017 | |
| Stage‡ | |||||||||
| I | 1 | 1 | |||||||
| II | 2.58 (2.47–2.69) | <0.001 | - | - | 0.81 (0.79–0.84) | <0.001 | - | - | |
| III | 6.69 (6.38–7.01) | <0.001 | - | - | 0.71 (0.67–0.75) | <0.001 | - | - | |
| ER | |||||||||
| Negative | 1 | 1 | |||||||
| Positive | 1.16 (1.11–1.21) | <0.001 | - | - | 1.45 (1.39–1.51) | <0.001 | - | - | |
| PR | |||||||||
| Negative | 1 | 1 | |||||||
| Positive | 0.99 (0.95–1.03) | 0.648 | - | - | 1.11 (1.07–1.15) | <0.001 | - | - | |
| HR | |||||||||
| Negative | 1 | 1 | 1 | 1 | |||||
| Positive | 1.18 (1.13–1.24) | <0.001 | 1.54 (1.44–1.64) | <0.001 | 1.41 (1.35–1.47) | <0.001 | 1.03 (0.99–1.08) | 0.158 | |
| Radiotherapy | |||||||||
| Without | 1 | 1 | 1 | 1 | |||||
| With | 0.80 (0.78–0.83) | <0.001 | 0.85 (0.82–0.88) | <0.001 | 0.70 (0.68–0.72) | <0.001 | 0.78 (0.75–0.8) | <0.001 | |
LP-BCSD = later period breast cancer-specific death; LP-non-BCSD = later period non-breast cancer-specific death; SHR = subdistribution hazard ratio; CI = confidence interval; HR = hormone receptor; IDC = infiltrating duct carcinoma; ILC = infiltrating lobular carcinoma; ER = estrogen receptor; PR = prognosis receptor; AJCC = American Joint Committee on Cancer.
*LP-BCSD and LP-non-BCSD were conducted using the Fine and Gray competing regression model, †Stage TNM, T, N-classification according to 8th edition of AJCC staging.